[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349092-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349092-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-ex-vivo-target-evaluation-of-phosphodiesterase-3-a-pde3a","Pan-cancer ex vivo target evaluation of phosphodiesterase 3 A (PDE3A)","","Phosphodiesterase 3 A (PDE3A) is a characterized enzyme central to cAMP-mediated signaling and related kinase pathways, and it has been proposed as an inflammation-associated stemness gene interacting with SLFN12. PDE3A is highly expressed across multiple human cancer types, motivating its evaluation as a therapeutic target. An ex vivo pan-cancer study assessed PDE3A expression across 24 cancer types and 59 molecular subtypes, linking results to drug screening of the PDE3A-SLFN12 molecular glue anagrelide in 250 patient-derived tumor models. Highest PDE3A expression appeared in melanomas, and anagrelide showed best efficacy in sarcomas with high PDE3A and SLFN12 expression, while sarcoma heterogeneity required further validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-ex-vivo-target-evaluation-of-phosphodiesterase-3-a-pde3a/349092/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-ex-vivo-target-evaluation-of-phosphodiesterase-3-a-pde3a/349092.png","ImageObject",300,407,{"name":42,"@type":43},"Melati","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the biological role of PDE3A highlighted in the study?","Question",{"text":63,"@type":64},"PDE3A is described as an enzyme involved in cAMP-mediated signaling and kinase-related pathways. It is also linked to inflammation-associated stemness through interaction with SLFN12, leading to blocked translation and apoptosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was PDE3A target potential evaluated across cancers?",{"text":68,"@type":64},"The study used patient-derived functional ex vivo tumor models covering 24 cancer types and 59 molecular subtypes. PDE3A protein expression was correlated with ex vivo drug screening using the PDE3A-SLFN12 molecular glue anagrelide.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic performance did anagrelide show and in which cancers?",{"text":72,"@type":64},"Anagrelide demonstrated the best therapeutic potential in sarcomas with high protein expression of both PDE3A and SLFN12. It also reported high PDE3A expression across melanomas, where the study indicated strong relevance for efficacy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349092,1790615840,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Journal of Molecular Medicine (2026) 104:69 [https://doi.org/10.1007/s00109-026-02677-7](https://doi.org/10.1007/s00109-026-02677-7)  \nORIGINAL ARTICLE  \nPan-cancer ex vivo target evaluation of phosphodiesterase 3 A (PDE3A)  \nKiesha Rice1 · Noora Lehtinen1,6 · EetuVälimäki1 · Janne Suhonen1 · Pekka Taimen2,3,4 · Kimmo Kettunen2,3,4,8 · Sami Ventelä2,5 · Juha Kononen6 · Harri Sihto7 · Juha K. Rantala1,9  \nReceived: 4 December 2025 / Revised: 17 April 2026 / Accepted: 22 April 2026 © The Author(s) 2026  \nAbstract  \nPhosphodiesterase 3 A (PDE3A) is a well-characterized enzyme that plays a crucial role in various cellular processes, including cAMP-mediated signaling, CREB-mediated induction of p21 and signaling through protein kinases A and G. PDE3A has also been suggested as an inflammation-associated stemness gene which upon interaction with protein SLFN12, leads to blocked protein translation and induction of apoptosis. PDE3A has been found to be highly expressed in several human cancer types including sarcomas, pancreatic ductal adenocarcinoma, non-small cell lung cancer and melanoma. PDE3A has thus emerged as a potential therapeutic cancer target. However, to fully understand the functional role and validate target potential of PDE3A in different human cancers, further research is needed. We report here a pan-cancer ex vivo study of PDE3A protein expression across 24 different cancer types represented by 59 different molecular subtypes correlated with ex vivo drug screening of PDE3A-SLFN12 molecular glue anagrelide in 250 patient derived functional tumor models. Results of the study identify highest PDE3A expression in melanomas and across different histological subtypes of sarcomas. Correlating with the expression profile of PDE3A, anagrelide was found to display best therapeutic potential in sarcomas with high protein expression of both PDE3A and SLFN12, though sarcoma heterogeneity warrants further subtype-specific validation.  \nKey message  \n● 250 patient samples included in a functional ex vivo target validation study.  \n● Proteomic profiling identifies high expression of PDE3A in several cancer types.  \n● Anagrelide shows best therapeutic efficacy in sarcomas and melanomas.  \n● Expression of PDE3B expression not correlating with efficacy of anagrelide.  \nKeywords PDE3A · Pan-cancer · Target evaluation · RPPA · Ex vivo drug screening · Anagrelide  \nKiesha Rice and Noora Lehtinen contributed equally to this work.  \n􀀍 Juha K. Rantala [rantala@misvik.com](rantala@misvik.com)  \n1 Misvik Biology Oy, Karjakatu 35 B, Turku FI-20520, Finland  \n2 Institute of Biomedicine, University of Turku, Turku, Finland  \n3 FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland  \n4 Department of Pathology, Laboratory Division, Turku University Hospital, Turku, Finland  \n5 Department for Otorhinolaryngology-Head and Neck Surgery, University of Turku and Turku University Hospital, Turku 20520, Finland  \n6 Docrates Cancer Center, Helsinki 00180, Finland  \n7 Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki 00014, Finland  \n8 Turku Prostate Cancer Consortium, University of Turku, Turku, Finland  \n9 Orion Pharma, Espoo 02200, Finland  \n1 3  \nIntroduction  \nPDE3A plays a multifaceted role in multiple cellular processes, including cAMP degradation, phosphorylation, dephosphorylation, and signaling. Its functions extend to the regulation of protein isoforms, protein biosynthesis, and the activity of other proteins such as PKA, PKG and SERCA2 . The diverse roles of PDE3A underscore its importance in physiological and pathological conditions, making it a potential target for therapeutic interventionsand several treatments have been identified that modulate PDE3A activity, including 8-chloro-cyclic adenosine monophosphate, anagrelide, cilostamide, cilostazol, estradiol, milrinone, thrombin and trequinsin, These treatments have been shown to affect various biological processes,","cbCaiqcMH0biBWFi","https://ap.wps.com/l/cbCaiqcMH0biBWFi","pdf",1532356,"English","# Abstract\n## Key message\n# Introduction","[{\"question\":\"What is the biological role of PDE3A highlighted in the study?\",\"answer\":\"PDE3A is described as an enzyme involved in cAMP-mediated signaling and kinase-related pathways. It is also linked to inflammation-associated stemness through interaction with SLFN12, leading to blocked translation and apoptosis.\"},{\"question\":\"How was PDE3A target potential evaluated across cancers?\",\"answer\":\"The study used patient-derived functional ex vivo tumor models covering 24 cancer types and 59 molecular subtypes. PDE3A protein expression was correlated with ex vivo drug screening using the PDE3A-SLFN12 molecular glue anagrelide.\"},{\"question\":\"What therapeutic performance did anagrelide show and in which cancers?\",\"answer\":\"Anagrelide demonstrated the best therapeutic potential in sarcomas with high protein expression of both PDE3A and SLFN12. It also reported high PDE3A expression across melanomas, where the study indicated strong relevance for efficacy.\"}]","Pan-cancer ex vivo target evaluation of phosphodiesterase 3 A (PDE3A) | PDF",1790081574,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d5ec1d58c14fad3a33d4be21cb7fa55.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3c7a7df1563ad33fdcd1d588f3bf6e9.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fefb5419883f657971739c0d5bcae2f5.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4f6bef43692b980a9177b6f322760be.webp",980,1301]